A new nasal-delivered nanotherapy shows promise against aggressive glioblastoma tumors. By activating the STING immune pathway using gold-core spherical nucleic acids, researchers were able to reach ...
A study by Brown University Health researchers has identified a crucial factor that may help improve treatment for ...
NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help ...
NovoCure remains a 'Sell' as TTFields' utility is largely capped at glioblastoma, with limited expansion potential. 2025 revenue grew 8% to $655 million, but new indications like NSCLC and ...
ImmunityBio, Inc. ( NASDAQ: IBRX), a commercial-stage immunotherapy company developing cytokine and cellular immunotherapies designed to restore immune competence, today announced updated Phase 2 ...
B7-H3–directed CAR T-cell therapy showed safety and tolerability in recurrent glioblastoma patients, with no dose-limiting toxicities or severe adverse effects observed. The study achieved a 44% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results